DK3661514T3 - Mavacamten til behandling af hypertrofisk kardiomyopati - Google Patents
Mavacamten til behandling af hypertrofisk kardiomyopatiInfo
- Publication number
- DK3661514T3 DK3661514T3 DK18759209.2T DK18759209T DK3661514T3 DK 3661514 T3 DK3661514 T3 DK 3661514T3 DK 18759209 T DK18759209 T DK 18759209T DK 3661514 T3 DK3661514 T3 DK 3661514T3
- Authority
- DK
- Denmark
- Prior art keywords
- mavacamten
- treatment
- hypertrophic cardiomyopathy
- hypertrophic
- cardiomyopathy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762541591P | 2017-08-04 | 2017-08-04 | |
| US201762584537P | 2017-11-10 | 2017-11-10 | |
| US201862639922P | 2018-03-07 | 2018-03-07 | |
| US201862671585P | 2018-05-15 | 2018-05-15 | |
| PCT/US2018/045180 WO2019028360A1 (en) | 2017-08-04 | 2018-08-03 | MAVACAMTEN FOR USE IN THE TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3661514T3 true DK3661514T3 (da) | 2025-12-15 |
Family
ID=63350605
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK18759209.2T DK3661514T3 (da) | 2017-08-04 | 2018-08-03 | Mavacamten til behandling af hypertrofisk kardiomyopati |
Country Status (19)
| Country | Link |
|---|---|
| US (5) | US20200054636A1 (da) |
| EP (2) | EP3661514B1 (da) |
| JP (3) | JP2020529996A (da) |
| KR (2) | KR20200035973A (da) |
| CN (2) | CN118593507A (da) |
| AU (2) | AU2018311974B2 (da) |
| CA (1) | CA3071948A1 (da) |
| DK (1) | DK3661514T3 (da) |
| FI (1) | FI3661514T3 (da) |
| IL (2) | IL322175A (da) |
| LT (1) | LT3661514T (da) |
| MA (1) | MA49760A (da) |
| MX (3) | MX2020001406A (da) |
| MY (1) | MY208231A (da) |
| RU (1) | RU2020109345A (da) |
| SG (2) | SG10202112960QA (da) |
| SM (1) | SMT202500413T1 (da) |
| UY (1) | UY37834A (da) |
| WO (1) | WO2019028360A1 (da) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE067913T2 (hu) | 2018-01-19 | 2024-11-28 | Cytokinetics Inc | Dihidrobenzofurán és indén analógok mint szív szarkomer gátlók |
| JP7438148B2 (ja) | 2018-06-26 | 2024-02-26 | サイトキネティックス， インコーポレイテッド | 心臓サルコメア阻害剤 |
| US12187712B2 (en) | 2018-06-26 | 2025-01-07 | Cytokinetics, Inc. | Cardiac sarcomere inhibitors |
| WO2020257609A1 (en) * | 2019-06-21 | 2020-12-24 | MyoKardia, Inc. | Diagnostics and treatments for cardiac disease |
| CN110698415B (zh) * | 2019-10-21 | 2023-05-09 | 上海先行医药开发有限公司 | 一种肌球蛋白抑制剂及其制备方法和用途 |
| AU2020378197A1 (en) * | 2019-11-10 | 2022-05-26 | MyoKardia, Inc. | Methods of treatment with myosin modulator |
| AU2021213748A1 (en) * | 2020-01-28 | 2022-08-25 | Assia Chemical Industries Ltd. | Solid state forms of Mavacamten and process for preparation thereof |
| CA3190060A1 (en) * | 2020-08-28 | 2022-03-03 | MyoKardia, Inc. | Methods of treatment with myosin modulator |
| JP2023550444A (ja) | 2020-11-20 | 2023-12-01 | 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 | トリアジンジオン系誘導体、その調製方法及びその医薬的応用 |
| WO2022162701A1 (en) * | 2021-02-01 | 2022-08-04 | Dr. Reddy's Laboratories Limited | Process for preparation of mavacamten and solid state forms thereof |
| CN117083275A (zh) | 2021-03-04 | 2023-11-17 | 赛特凯恩蒂克公司 | 心脏肌节抑制剂 |
| CN112939876A (zh) * | 2021-03-10 | 2021-06-11 | 杭州科巢生物科技有限公司 | Mavacamten的晶型I及其制备方法 |
| WO2022189599A1 (en) | 2021-03-12 | 2022-09-15 | Sandoz Ag | Crystalline forms of mavacamten for the treatment of hcm |
| HUE070699T2 (hu) | 2021-07-16 | 2025-06-28 | Cytokinetics Inc | Afikamtén dózisadagolási obstruktív hipertrófiás kardiomiopátia kezelésére |
| EP4404846B1 (en) * | 2021-09-24 | 2025-10-08 | Koninklijke Philips N.V. | Methods and systems for generating likelihood of heart failure with preserved ejection fraction (hfpef) |
| WO2024097284A1 (en) * | 2022-11-02 | 2024-05-10 | MyoKardia, Inc. | Mavacamten and derivatives thereof for use in treating atrial dysfunction |
| KR20250174911A (ko) | 2023-03-27 | 2025-12-15 | 엣지와이즈 테라퓨틱스, 인크. | 퀴놀리논 아미드 화합물 및 이의 용도 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SMT202000071T1 (it) * | 2013-06-21 | 2020-03-13 | Myokardia Inc | Composti di pirimidinadione contro le condizioni cardiache |
-
2018
- 2018-08-03 RU RU2020109345A patent/RU2020109345A/ru unknown
- 2018-08-03 SG SG10202112960QA patent/SG10202112960QA/en unknown
- 2018-08-03 WO PCT/US2018/045180 patent/WO2019028360A1/en not_active Ceased
- 2018-08-03 CN CN202410743651.3A patent/CN118593507A/zh active Pending
- 2018-08-03 MX MX2020001406A patent/MX2020001406A/es unknown
- 2018-08-03 KR KR1020207004507A patent/KR20200035973A/ko not_active Ceased
- 2018-08-03 KR KR1020257024814A patent/KR20250116181A/ko active Pending
- 2018-08-03 MY MYPI2020000493A patent/MY208231A/en unknown
- 2018-08-03 IL IL322175A patent/IL322175A/en unknown
- 2018-08-03 MA MA049760A patent/MA49760A/fr unknown
- 2018-08-03 CN CN201880050881.4A patent/CN111182901A/zh active Pending
- 2018-08-03 SG SG11202000549TA patent/SG11202000549TA/en unknown
- 2018-08-03 CA CA3071948A patent/CA3071948A1/en active Pending
- 2018-08-03 FI FIEP18759209.2T patent/FI3661514T3/fi active
- 2018-08-03 SM SM20250413T patent/SMT202500413T1/it unknown
- 2018-08-03 JP JP2020505487A patent/JP2020529996A/ja active Pending
- 2018-08-03 EP EP18759209.2A patent/EP3661514B1/en active Active
- 2018-08-03 DK DK18759209.2T patent/DK3661514T3/da active
- 2018-08-03 AU AU2018311974A patent/AU2018311974B2/en active Active
- 2018-08-03 LT LTEPPCT/US2018/045180T patent/LT3661514T/lt unknown
- 2018-08-03 EP EP25196218.9A patent/EP4659806A2/en active Pending
- 2018-08-06 UY UY0001037834A patent/UY37834A/es not_active Application Discontinuation
-
2019
- 2019-03-26 US US16/364,322 patent/US20200054636A1/en not_active Abandoned
-
2020
- 2020-01-28 IL IL272300A patent/IL272300B2/en unknown
- 2020-02-04 MX MX2024008096A patent/MX2024008096A/es unknown
- 2020-02-04 MX MX2024000348A patent/MX2024000348A/es unknown
-
2022
- 2022-03-23 US US17/701,863 patent/US20220226324A1/en not_active Abandoned
- 2022-06-16 US US17/842,389 patent/US20220313695A1/en not_active Abandoned
-
2023
- 2023-02-01 JP JP2023014110A patent/JP2023065372A/ja active Pending
-
2024
- 2024-06-07 AU AU2024203872A patent/AU2024203872A1/en active Pending
- 2024-09-06 US US18/827,049 patent/US20240423981A1/en not_active Abandoned
- 2024-11-01 JP JP2024192836A patent/JP2025020292A/ja active Pending
-
2025
- 2025-03-18 US US19/082,967 patent/US20250213565A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3661514T3 (da) | Mavacamten til behandling af hypertrofisk kardiomyopati | |
| LT3810602T (lt) | Junginiai | |
| DK3512850T3 (da) | Inhibitorer af menin-mll-interaktionen | |
| DK3468966T3 (da) | Inhibitorer af menin-mll-interaktionen | |
| DK3785733T3 (da) | Farmaceutisk sammensætning til behandling af autisme | |
| DK3556775T3 (da) | Anti-lag-3 antistoffer til behandling af hæmatologiske maligniteter | |
| DK3325443T3 (da) | Fremgangsmåde til fremstilling af pridopidin | |
| EP3609871A4 (en) | ARYL CYCLOPROPYL-AMINO-ISOQUINOLINYL AMIDE COMPOUNDS | |
| DK3503890T3 (da) | Anvendelse af pridopidin til behandling af dystonier | |
| DK3524255T3 (da) | Sammensætning til behandling af acne | |
| PT4039675T (pt) | Compostos de fenil-2-hidroxi-acetilamino-2-metil-fenilo | |
| DK3436074T3 (da) | Thiazolidforbindelser til behandling af virale infektioner | |
| DK4101454T3 (da) | Sammensætninger til behandling af hypertension | |
| DK3318115T3 (da) | Maskine til behandling af svinegylle | |
| IL279620B1 (en) | Compounds | |
| DK3331610T3 (da) | Midler til anvendelse til behandling af gliom | |
| DK3638293T3 (da) | Sammensætninger til behandling af cancer | |
| IL282311A (en) | Use of reboxetine to treat narcolepsy | |
| DK3478713T3 (da) | Sammensætninger til behandling af amyloidose | |
| DK3618845T3 (da) | Peptider til behandling af diabetes | |
| EP3850168C0 (fr) | Elément de construction | |
| DK3463328T3 (da) | Seladelpar til behandling af primær biliær cholangitis | |
| DK3672941T3 (da) | Pyridylpyridonforbindelser | |
| DK3448340T3 (da) | Applikationshjælpemiddel til behandling af sår | |
| EP3829866A4 (en) | CONSTRUCTION ELEMENT |